Treatment for Thrombocytopenic Purpura

Dova Site, York, PA
Thrombocytopenic Purpura
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether a drug called avatrombopag is safe and tolerated when given to people who have stopped taking eltrombopag or romiplostim.

Eligible Conditions
  • Idiopathic Thrombocytopenic Purpura (ITP)

Treatment Effectiveness

Phase-Based Effectiveness

3 of 3
Phase 4
This is further along than 93% of similar trials

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Screening through Day 90 or End of Study

Day 90
Platelet counts
Safety and Tolerability (adverse events)
Subject reported outcomes

Trial Safety

Phase-Based Safety

3 of 3
This is further along than 85% of similar trials

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

0 Treatment Group

100 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · Phase 4

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: screening through day 90 or end of study

Who is running the clinical trial?

Dova PharmaceuticalsLead Sponsor
5 Previous Clinical Trials
248 Total Patients Enrolled
Sobi, Inc.Lead Sponsor
10 Previous Clinical Trials
506 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Have any additional investigations been conducted regarding this treatment regimen?

"The initial research on this treatment was conducted at Dova Site in 2018, and since then there have been 19 similar trials that have concluded. Currently, 11 studies are actively recruiting participants with a majority of them based out of New Orleans, Louisiana." - Anonymous Online Contributor

Unverified Answer

Are there any openings remaining in this clinical research program?

"Going by the information on, this trial is currently in search of test subjects. It was originally published on March 15th 2021 and subsequently modified last November 1st 2022." - Anonymous Online Contributor

Unverified Answer

How many individuals are engaged in this research study?

"To complete this study, 100 volunteers fitting the established criteria must be recruited. These patients can register for participation at Sobi Site 124 in New Orleans and additionally at Sobi Site 125 in Saint Petersburg, Florida." - Anonymous Online Contributor

Unverified Answer

To what degree is this treatment hazardous for individuals?

"This medication has been approved for use and thus is given a score of 3 on the safety scale. This implies that phase 4 trials were conducted to confirm its efficacy and safety." - Anonymous Online Contributor

Unverified Answer

Is this trial a pioneering endeavor?

"Presently, 11 trials for this pharmaceutical are taking place in 78 cities and 11 countries. The initial study was conducted by Sobi Incorporated in 2018 with a population of 122 volunteers which successfully completed the Phase 3 clinical trial phase. 19 additional studies have been finalized since then." - Anonymous Online Contributor

Unverified Answer

How many venues are presently offering this research initiative?

"There are 36 centres offering this research opportunity, including Sobi Site 124 in New Orleans, Sobi Site 125 in Saint Petersburg and Sobi Site 126 in Peoria." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.